About Biomodal
Biomodal is a company based in Cambridge (United Kingdom) founded in 2012.. Biomodal has raised $164.1 million across 5 funding rounds from investors including Syncona, Temasek and European Union. Biomodal offers products and services including duet multiomics solution evoC and duet multiomics solution +modC. Biomodal operates in a competitive market with competitors including Aligned Bio, Singular Bio, YouScript, Nooma Bio and Annogen, among others.
- Headquarter Cambridge, United Kingdom
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$164.1 M (USD)
in 5 rounds
-
Latest Funding Round
$88 M (USD), Series D
Nov 02, 2021
-
Investors
Syncona
& 9 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biomodal
Biomodal offers a comprehensive portfolio of products and services, including duet multiomics solution evoC and duet multiomics solution +modC. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enables 6-base genome sequencing from single DNA samples.
Assesses canonical bases and modified cytosine in one experiment.
Funding Insights of Biomodal
Biomodal has successfully raised a total of $164.1M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $88 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series D — $88.0M
-
First Round
First Round
(29 Oct 2014)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2021 | Amount | Series D - Biomodal | Valuation | Temasek | |
| Jan, 2020 | Amount | Grant - Biomodal | Valuation |
investors |
|
| Apr, 2018 | Amount | Series C - Biomodal | Valuation | Ahren |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Biomodal
Biomodal has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Syncona, Temasek and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
An investment platform is provided for diverse sectors and geographies.
|
Founded Year | Domain | Location | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Early, mid, and late-stage investments are made in science sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Biomodal
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Biomodal
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Biomodal Comparisons
Competitors of Biomodal
Biomodal operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aligned Bio, Singular Bio, YouScript, Nooma Bio and Annogen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Nanowire-based sensors and alignment technologies are provided for molecular detection.
|
|
| domain | founded_year | HQ Location |
Tools for single molecule detection are developed by Singular Bio.
|
|
| domain | founded_year | HQ Location |
Clinical decision support software for drug interactions is developed.
|
|
| domain | founded_year | HQ Location |
Dual-nanopore technology is developed for genome-wide structural and epigenetic variations.
|
|
| domain | founded_year | HQ Location |
Genetic variations are screened via a specialized genomic platform.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Biomodal
Frequently Asked Questions about Biomodal
When was Biomodal founded?
Biomodal was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Where is Biomodal located?
Biomodal is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Who is the current CEO of Biomodal?
Peter Fromen is the current CEO of Biomodal.
Is Biomodal a funded company?
Biomodal is a funded company, having raised a total of $164.1M across 5 funding rounds to date. The company's 1st funding round was a Series C of $37.7M, raised on Oct 29, 2014.
What does Biomodal do?
Biomodal was founded in 2012 in Cambridge, United Kingdom, within the biotechnology sector. DNA sequencing tools and technologies are developed by the company for research and diagnostic applications. A duet multi-omics solution, including modC, is provided, which employs next-generation sequencing to obtain genetic and epigenetic methylation data. These tools support areas such as cancer research, non-invasive prenatal testing, and precision medicine.
Who are the top competitors of Biomodal?
Biomodal's top competitors include Aligned Bio, Singular Bio and YouScript.
What products or services does Biomodal offer?
Biomodal offers duet multiomics solution evoC and duet multiomics solution +modC.
Who are Biomodal's investors?
Biomodal has 10 investors. Key investors include Syncona, Temasek, European Union, University of Cambridge, and Third Point.
What is Biomodal's valuation?
The valuation of Biomodal is $163.5M as of Apr 2018.